From a pharmacological perspective, specific α2-AR agonists, administered alone or in combination with antipsychotics may enhance neurocognitive functions but also reduce positive and even negative schizophrenia symptoms leading to potentially high clinical relevance for treatment of this disorder. The gene discussed is ADORA2A; the disease is schizophrenia.